| 23086647 | [Expression of RRM1 and ERCC1 genes in tumor tissues and peripheral blood lymphocytes of advanced non-small cell lung cancer]. | Zhejiang Da Xue Xue Bao Yi Xue Ban | 2012 Sep | Zhang GB | - |
| 23155271 | Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer. | Anticancer Res | 2012 Nov | Pesta M | - |
| 19552012 | [ERCC1 and RRM1 genes in lung cancer]. | Rev Port Pneumol | 2009 Jul-Aug | Carvalho L | - |
| 28411237 | Physical interaction between human ribonucleotide reductase large subunit and thioredoxin increases colorectal cancer malignancy. | J Biol Chem | 2017 Jun 2 | Lou M | doi: 10.1074/jbc.M117.783365 |
| 28624910 | Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy? | J Cancer Res Clin Oncol | 2017 Aug | Mannargudi MB | doi: 10.1007/s00432-017-2457-8 |
| 20467918 | ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. | Med Oncol | 2011 Dec | Su C | doi: 10.1007/s12032-010-9553-9 |
| 24591771 | First-line gemcitabine plus cisplatin in nonsmall cell lung cancer patients. | Dis Markers | 2014 | Li Y | doi: 10.1155/2014/960458 |
| 24578158 | Association of novel gene polymorphisms RRM1 -756T>C and -269 C>A with breast cancer. | J Clin Lab Anal | 2014 Jul | Chen DR | doi: 10.1002/jcla.21682 |
| 12687015 | RRM1-induced metastasis suppression through PTEN-regulated pathways. | Oncogene | 2003 Apr 10 | Gautam A | - |
| 15172981 | An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. | Cancer Res | 2004 Jun 1 | Davidson JD | - |
| 26542178 | Prognostic value of ERCC1, RRM1, BRCA1 and SETDB1 in early stage of non-small cell lung cancer. | Clin Transl Oncol | 2016 Aug | Lafuente-Sanchis A | doi: 10.1007/s12094-015-1440-6 |
| 23803067 | mRNA expression and clinical significance of ERCC1, BRCA1, RRM1, TYMS and TUBB3 in postoperative patients with non-small cell lung cancer. | Asian Pac J Cancer Prev | 2013 | Han Y | - |
| 24861915 | Investigation of the association of hRRM1 and p53R2 gene polymorphisms in head and neck squamous cell carcinomas. | Med Oncol | 2014 Jul | Orhan KS | doi: 10.1007/s12032-014-0012-x |
| 26637889 | High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma. | Anticancer Res | 2015 Dec | Zimling ZG | - |
| 25497672 | RRM1 modulates mitotane activity in adrenal cancer cells interfering with its metabolization. | Mol Cell Endocrinol | 2015 Feb 5 | Germano A | doi: 10.1016/j.mce.2014.11.027 |
| 26323924 | The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer. | J Cancer Res Ther | 2015 Aug | Xu XL | doi: 10.4103/0973-1482.163839. |
| 21370501 | RRM1 gene expression in peripheral blood is predictive of shorter survival in Chinese patients with advanced non-small-cell lung cancer treated by gemcitabine and platinum. | J Zhejiang Univ Sci B | 2011 Mar | Wang LR | doi: 10.1631/jzus.B1000197. |
| 25837929 | Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors. | J Pharmacol Sci | 2015 Mar | Minami K | doi: 10.1016/j.jphs.2015.01.006 |
| 14729598 | In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. | Cancer Res | 2004 Jan 1 | Shao J | - |
| 20211060 | [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines]. | Zhonghua Zhong Liu Za Zhi | 2010 Jan | Liu XQ | - |
| 25638032 | Non-enzymatic action of RRM1 protein upregulates PTEN leading to inhibition of colorectal cancer metastasis. | Tumour Biol | 2015 Jun | Qi H | doi: 10.1007/s13277-015-3137-4 |
| 19543324 | Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma. | Oncogene | 2009 Aug 13 | Akita H | doi: 10.1038/onc.2009.158 |
| 17131328 | Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer. | Int J Cancer | 2007 Mar 15 | Nakahira S | - |
| 21424698 | A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer. | Invest New Drugs | 2012 Jun | El-Khoueiry AB | doi: 10.1007/s10637-011-9658-9 |
| 26718430 | Investigation of some DNA repair genes association in non small cell lung cancer. | Cell Mol Biol (Noisy-le-grand) | 2015 Dec 19 | Coskunpinar E | - |
| 24155212 | Expression of RRM1 and RRM2 as a novel prognostic marker in advanced non-small cell lung cancer receiving chemotherapy. | Tumour Biol | 2014 Mar | Wang L | doi: 10.1007/s13277-013-1255-4 |
| 23552804 | Ribonucleotide reductase expression in cervical cancer: a radiation therapy oncology group translational science analysis. | Int J Gynecol Cancer | 2013 May | Kunos CA | doi: 10.1097/IGC.0b013e31828b4eb5. |
| 26650486 | The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient. | Clin Transl Oncol | 2016 Sep | Mlak R | doi: 10.1007/s12094-015-1461-1 |
| 23922955 | Ribonucleotide reductase large subunit M1 predicts poor survival due to modulation of proliferative and invasive ability of gastric cancer. | PLoS One | 2013 Jul 29 | Wang Q | doi: 10.1371/journal.pone.0070191 |
| 21264835 | Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. | Cancer | 2011 Jul 15 | Kim R | doi: 10.1002/cncr.25883 |
| 17602053 | An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients. | Oncologist | 2007 Jun | Rha SY | - |
| 24361227 | Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy. | Eur J Cancer | 2014 Mar | Lee SY | doi: 10.1016/j.ejca.2013.11.028 |
| 21642870 | Differential effect of polymorphisms of CMPK1 and RRM1 on survival in advanced non-small cell lung cancer patients treated with gemcitabine or taxane/cisplatinum. | J Thorac Oncol | 2011 Aug | Ryu JS | doi: 10.1097/JTO.0b013e3182208e26. |
| 20226083 | RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy. | J Hematol Oncol | 2010 Mar 13 | Dong S | doi: 10.1186/1756-8722-3-10. |
| 23991987 | Predictive and prognostic roles of ribonucleotide reductase M1 in patients with pancreatic cancer treated with gemcitabine: a meta-analysis. | Asian Pac J Cancer Prev | 2013 | Zhang X | - |
| 19304340 | Polymorphisms of the ribonucleotide reductase M1 gene and sensitivity to platin-based chemotherapy in non-small cell lung cancer. | Lung Cancer | 2009 Dec | Feng JF | doi: 10.1016/j.lungcan.2009.02.015 |
| 27908619 | Correlation of DNA Repair Gene Polymorphisms With Clinical Outcome in Patients With Locally Advanced Non-Small-Cell Lung Cancer Receiving Induction Chemotherapy Followed by Surgery. | Clin Lung Cancer | 2017 Mar | Santarpia M | doi: 10.1016/j.cllc.2016.08.007 |
| 28507282 | P53 suppresses ribonucleotide reductase via inhibiting mTORC1. | Oncotarget | 2017 Jun 20 | He Z | doi: 10.18632/oncotarget.17440. |
| 27587543 | Polymorphisms in cancer-related pathway genes and lung cancer. | Eur Respir J | 2016 Oct | Lee SY | doi: 10.1183/13993003.02040-2015 |
| 29214667 | Effect of ribonucleotide reductase M1 expression on overall survival in patients with pancreatic cancer receiving gemcitabine chemotherapy: A literature-based meta-analysis. | J Clin Pharm Ther | 2018 Apr | Han QL | doi: 10.1111/jcpt.12655 |
| 28066957 | Overexpression of ribonucleotide reductase subunit M1 protein predicts shorter survival in metastatic bladder cancer patients treated with gemcitabine-containing combination chemotherapy. | Int J Urol | 2017 Mar | Matsumura N | doi: 10.1111/iju.13274 |
